Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats

Kidney International

Volumn 53, Issue 5, 1998, Pages 1305-1313

  Murakami, Hideyuki ^a   Yayama, Katsutoshi ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Gene delivery; Gentamycin; Infection; Kallikrein kinin system; Nephrotoxicity; Renal injury

Indexed keywords

BETA GALACTOSIDASE; GENTAMICIN; KALLIKREIN; KININ; MESSENGER RNA; NITRATE; NITRIC OXIDE; NITRITE; NITROGEN; SODIUM CHLORIDE; UREA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; GENE TARGETING; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY MASS; KIDNEY NECROSIS; KIDNEY TUBULE DAMAGE; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031817101     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00867.x     Document Type: Article

References (37)

1. MATHEW TH: Drug-induced renal disease. Med J Aust 156:724-729, 1992
2. HUMES HD: Aminoglycoside nephrotoxicity. Kidney Int 33:900-911, 1988
3. HOSTETLER KY, HALL LB: Inhibition of kidney lysosomal phospholipases A and C by aminoglycoside antibiotics: Possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci USA 79:1663-1667, 1982
4. LAURENT G, KISHORE BK, TULKENS PM: Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 40: 2383-2392, 1990
5. CHAN MK, CHAN KW, NG WL: Amelioration of gentamicin nephrotoxicity by phospholipids. Nephrol Dial Transplant 6:608-614, 1991
6. CLEMENTS JA: The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocrine Rev 10:393-419, 1989
7. BHOOLA KD, FIGUEROA CD, WORTHY K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80, 1992
8. BERRY TD, HASSTEDT SJ, HUNT SC, WU LL, SMITH JB, ASH KO, KUIDA H, WILLIAMS RR: A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13:3-8, 1989
9. MARGOLIUS HS, GELLER R, DEJONG, W, PISANO JJ, SJOERDSMA A: Altered urinary kallikrein excretion in rats with hypertension. Circ Res 30:358-362, 1972
10. FAVARO S, BAGGIO B, ANTONELLO A, ZEN A, CANNELLA G, TODESCO S, BORSATTI A: Renal kallikrein content of spontaneously hypertensive rats, Clin Sci Mol Med 49:69-71, 1975
11. GELLER RG, MARGOLIUS HA, PISANO JJ, KEISER HR: Urinary kalllikrein excretion in spontaneously hypertensive rats. Cire Res 36 (Suppl 1):103-106, 1975
12. ADER JL, POLLOCK DM, BUTTERFIELD MI, ARENDSHORST WJ: Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am J Physiol 248:F396-F403, 1985
13. UEHARA Y, HIRAWA N, KAWABATA Y, SUZUKI T, OHSHIMA N, OKA K, IKEDA T, GOTO A, TOYO-OKA T, KIZUKI K, OMATA M: Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24:770-778, 1994
14. CHAO J, ZHANG, JJ, LIN KF, CHAO L: Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther (in press)
15. YAYAMA K, WANG C, CHAO L, CHAO J: Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension (in press)
16. CHAO J, JIN L, CHEN LM, CHEN VC, CHAO L: Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther 7:901-911, 1996
17. BAUER JD: Carbohdrates and nitrogen compounds, in Clinical Laboratory Methods (9th ed), St. Louis, The C.V. Mosby Company, 1982, pp 472-505
18. WANG C, CHAO L, CHAO J: Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95:1710-1716, 1995
19. SESSA WC, PRITCHARD K, SEYEDI N, WANG J, HINTZE TH: Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 74:349-353, 1994
20. SHIMAMOTO K, TANAKA S, NAKAO T, ANDO T, NAKAHASHI Y, SAKUMA M, MIYAHARA M: Measurement of urinary kallikrein activity by kinin radioimmunoassay. Jpn Circ J 43:147-152, 1979
21. FITZGIBON WR, JAFFA AA, MAYFIELD RK, PLOTH DW: Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Hypertension 27:235-244, 1996
22. ALI BH: Gentamicin nephrotoxicity in humans and animals: Some recent research. Gen Pharmacol 26:1477-1487, 1995
23. KACEW S, BERGERON MG: Pathogenic factors in aminoglycoside-induced nephrotoxicity. Toxicol Lett 51:241-259, 1990
24. COLLIER VU, LIETMAN PS, MITCH WE: Evidence for luminal uptake of gentamicin in the perfused rat kidney. J Pharmacol Exp Ther 210:247-251, 1979
25. ORFILA C, BOMPART G, LEPERT JC, SUC JM, GIROLAMI JP: Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats. Histochem J 25:772-777, 1993
26. GIROLAMI JP, ORFILA C, CABOS BOUTOT G, PÉCHER C, BASCANDS JL, COLLE A: Early acute effects of mercuric chloride on synthesis and release of kallikrein and on distal tubular morphology of rat renal cortical slices. Renal Physiol Biochem 13:223-232, 1990
27. BOMPART G, PÉCHER C, PREVOT D, GIROLAMI JP: Mild renal failure induced by subchronic exposure to molybdenum: Urinary kallikrein excretion as a marker of distal tubular effects. Toxicol Lett 52:293-300, 1990
28. GIROLAMI JP, BASCANDS JL, PÉCHER C, CABOS JP, MOATTI JF, MERCIER JM, HAGUENOER JM, MANUEL Y: Renal kallikrein excretion as a distal nephrotoxicity marker during cadmium exposure in rats. Toxicology 55:117-129, 1989
29. MORIN NJ, LAURENT G, NONCLERCO D, TOUBEAL G, HEUSON-STIENNON JA, BERGERON MG, BEAUCHAMP D: Epidermal growth factor accelerates renal tissue repair in a model of gentamicin nephrotoxicity in rats. Am J Physiol 263:F806-F811, 1992
30. BEIERWALTES WH, CARRETERO OA, SCICLI AG: Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol 255:F408-F414, 1988
31. KATORI M, MAJIMA M: Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol 70:95-128, 1996
32. ROMAN RJ, KALDUNSKI ML, SCICLI AG, CARRETERO OA: Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol 255:F690-F698, 1988
33. HISHIDA A, NAKAJIMA T, YAMADA M, KATO A, HONDA N: Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Renal Failure 16:109-116, 1994
34. LINZ W, SCHÖLKENS BA, GANTEN D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 11:1325-1350, 1989
35. LINZ W, SCHÖLKENS BA: Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20(Suppl 9):S83-S90, 1992
36. JIN L, ZHANG JJ, CHAO L, CHAO J: Gene therapy in hypertension: Adenovirus-mediated kallikrein gene delivery in hypertesive rats. Hum Gene Ther 8:1753-1761, 1997
37. SOBERON L, BOWMAN RL, PASTORIZA-MUNOZ E, KALOYANIDES GJ: Comparative nephrotoxicities of gentamicin. netilmicin and tobramycin in the rat. J Pharmacol Exp Ther 210:334-343, 1979